Retinitis Pigmentosa
Conditions
Interventions
Intervention type:DRUG
Name of intervention:Sodium valproate
Dose form / Japanese Medical Device Nomenclature:TABLET
Route of administration / Site of application:ORAL
Dose per administration:200
0
mg
Sponsors
Yasuhiko Hirami
Masayo Takahashi, Yasuo Kurimoto
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with Retinitis Pigmentosa with decreased visual acuity less than 0.7 and 0.1 or better in decimal visual acuity, and visual field less than 10 degrees by I-4 in Goldmann kinetic perimetry
Exclusion criteria
Exclusion criteria: 1) Patients with retinal degeneration secondary to ocular infection or inflammation 2) Patients with ocular disease other than Retinitis Pigmentosa 3) Patients with pregnancy or breast-feeding 4) Patients with abnormality in liver function or urea cycle 5) Patients with any drug allergy 6) Patients with bipolar disorder and suicide attempt 7) Patients using following drugs; carbapenem antibiotic, barbiturate, phenytoin, carbamazepine, ethosuximide, amitoripuchin, norutoripuchin, kuropazamu, lamotrigine, salicylic acid, benzodiazepines, warfarin, erythromycin, cimetidine, clonazepam 8) any other case that research physicians decided to be inappropriate for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in best corrected visual acuity | — |
Countries
Japan
Contacts
Public ContactYasuhiko Hirami
Institute for Biomedical Research and Innovation Hospital
Outcome results
None listed